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Abstract
Treatment options for severe acute respiratory syndrome‐related coronavirus‐2
(SARS‐CoV‐2) are limited with no clarity on efficacy and safety profiles. We per-
formed a systematic review and meta‐analysis of studies on patients ≥18 years
reporting data on therapeutic interventions in SARS‐CoV‐2. Primary outcome was
all‐cause mortality and secondary outcomes were rates of mechanical ventilation,
viral clearance, adverse events, discharge, and progression to severe disease. Pooled
rates and odds ratios (OR) were calculated. Twenty‐nine studies with 5207 patients
were included. Pooled all‐cause mortality in intervention arm was 12.8% (95%
confidence interval [CI]: 8.1%‐17.4%). Mortality was significantly higher for studies
using hydroxychloroquine (HCQ) for intervention (OR: 1.36; 95% CI: 0.97‐1.89).
Adverse events were also higher in HCQ subgroup (OR: 3.88; 95% CI: 1.60‐9.45).
There was no difference in other secondary outcomes. There is a need for well‐
designed randomized clinical trials for further investigation of every therapeutic
intervention for further insight into different therapeutic options.
K E YWORD S
COVID‐19, HCQ, hydroxychloroquine, meta‐analysis, SARS‐CoV‐2
1 | INTRODUCTION
Severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2)
is the 7th virus of the coronavirus family known to infect humans.1 By
March, theWorld Health Organization (WHO) had declared SARS‐CoV‐2
as a pandemic, the third pandemic in the 21st century after the SARS
outbreak in 2003 and H1N1 influenza in 2009. SARS‐CoV‐2 tends to
cause a plethora of symptoms with fever, cough, myalgia, fatigue, loss of
taste, appetite, and diarrhea to name a few. It is also known to affect
multiple organ systems leading to acute respiratory distress syndrome,
encephalitis, myocarditis, hepatitis, acute kidney injury, and hypercoa-
gulable state leading to stroke and pulmonary embolism. The COVID‐19
disease caused by SARS‐CoV‐2 can be classified as mild, moderate,
severe, and critical disease based on clinical, imaging and laboratory
parameters.2 The natural history of the disease is such that most
patients typically have mild disease with spontaneous resolution of
symptoms by 10 to 14 days needing symptomatic management and
home self‐quarantine. Elderly population, as well as patients with
medical comorbidities, are at higher risk of developing moderate to
severe disease.3 As per the Chinese Center for Disease Control and
Abbreviations: CI, confidence interval; COVID‐19, coronavirus disease 2019; FDA, Food and Drug Administration; HCQ, hydroxychloroquine; IQR, interquartile range; NIH, National Institute
of Health; NNH, number needed to harm; NNT, number needed to treat; OR, odds ratio; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta‐Analyses; RCT, randomized
controlled trials; SARS‐CoV‐2, severe acute respiratory syndrome‐related coronavirus‐2; WHO, World Health Organization.
Article summary line:
The use of hydroxychloroquine was associated with increased mortality and adverse event rates in Severe acute respiratory syndrome‐related coronavirus‐2 infection and other therapeutic
interventions did not show any difference in outcomes.
Prevention data in a cohort of 72 314 patients, clinical deterioration
tends to typically occur in the second week of onset of symptoms with
need for hospitalization and close monitoring in 14% of patients and
around 5% of patients require invasive ventilation.4 Several therapeutic
interventions like Hydroxychloroquine (HCQ), Chloroquine, Remdesivir,
Corticosteroids, Tocilizumab, and convalescent plasma therapy have
been attempted, but currently, there is no known intervention that has
reduced mortality in COVID‐19 patients. These questions bring into fo-
cus the need of a comprehensive systematic review of the published
literature to collate the available evidence. The aim of this systematic
review and meta‐analysis is to assess if any intervention provides mor-
tality benefit, other clinically relevant outcomes, and also ascertain the
safety profile.
2 | METHODS
This systematic review was performed as per the Preferred Reporting
Items for Systematic Reviews and Meta‐Analyses recommendations.5
The protocol is provided as Appendix 1. Institutional review board
approval was not required for this study since no patient identifiers
were disclosed.
2.1 | Data sources
A systematic electronic search was performed in PubMed/MEDLINE,
Embase, Cochrane Central, Google Scholar, MedRxiv databases to
identify published and prepublished studies reporting outcomes re-
lated to interventions for SARS‐CoV‐2 infection, from 1 December
2019 to 11 May 2020. The Medical Subject Heading/Entree terms is
provided in Appendix 2. An independent review of the abstracts and
full paper articles was done (VT and BV). The duplicates were
removed and the titles of articles were evaluated. The full‐length
papers of the shortlisted articles were assessed for the eligibility
criteria. The articles that fulfilled the inclusion criteria were short-
listed for final systematic review. The included study references were
cross‐searched for additional studies. The articles were reviewed
independently by two authors (VT and BV) and any disagreement
was resolved by consensus with a third author (MR). Reasons for
excluding studies were documented.
2.2 | Eligibility criteria
The inclusion criteria were as follows: (a) studies reporting outcomes
for treatment in SARS‐CoV‐2 infection; (b) all studies including ran-
domized controlled trials (RCTs), prospective, retrospective, and case
series; (c) full‐length studies; (d) patients more than 18 years of age.
Exclusion criteria were: (a) preclinical studies, epidemiological, and
descriptive studies without intervention for SARS‐CoV‐2 patients; (b)
abstracts.
2.3 | Data extraction and quality assessment
The data were extracted by two authors independently into pre-
defined forms. The following data were extracted from the studies:
first author, mean age, study design, number of patients, gender, rates
of: mortality, clinical improvement, mechanical ventilation, progression
to severe disease, viral clearance, discharge, and adverse events. Data
for both intervention and control arms (for available studies) were
extracted separately. Quality assessment was performed only for
RCTs as most of the other studies were retrospective in nature with
short hospital courses for duration of treatment. Cochrane risk bias
tool was used for study quality assessment for RCTs.6
2.4 | Definitions and outcomes
The definitions of outcomes that were assessed are provided in
Appendix 3. The intervention arm consisted of patients receiving the
drug or the therapeutic intervention while the control arm patients
received standard of care treatment for SARS‐CoV‐2 without a
specific intervention. The primary outcomes were the all‐cause
mortality in the intervention arm and in comparison, with control
arm. The secondary outcomes were rates of clinical recovery, need
for mechanical ventilation, viral clearance, radiological improvement,
discharge, and adverse events in intervention arm and comparison
with control arm. Median duration for viral clearance and clinical
recovery was also calculated from available studies. Number needed
to treat (NNT) and number needed to harm (NNH) were defined as
the number of patients who needed to be treated to provide benefit
or harm in at least one patient, comparing intervention and control
arms for respective outcomes.
2.5 | Statistical analysis
Percentages for categorical variables and median with interquartile
range (IQR) for continuous variables were presented. Differences in
medians were calculated using the Mann‐Whitney‐Wilcoxon test.
Proportions with pooled rates with 95% confidence intervals (CIs)
were calculated for individual arms. Odds ratios (OR) comparing with
control arm were reported with 95% CI and P value of less than .05
was considered statistically significant. Random effects model
described by DerSimonian and Laird was used for analysis. Corre-
sponding forest plots were constructed for both primary and
secondary outcomes. NNT and NNH were calculated using the inverse
of the differences in benefit or harm between the intervention and
control arms for the respective outcomes. Study heterogeneity was
assessed using Inconsistency index (I2 statistic) with low, moderate,
substantial, and considerable heterogeneity indicated by I2 value of 0%
to 30%, 31% to 60%, 61% to 75%, and 76% to 100%, respectively. All
analyses were performed using statistical softwares Open Meta ana-
lyst (CEBM, Brown University, RI) and Review Manager Version 5.3
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(The Nordic Cochrane Center, Copenhagen, Denmark). Subgroup
analyses were performed for the following, when data were available
and also to address heterogeneity in primary outcome if present: (a)
intervention specific; (b) disease severity specific; (c) RCTs only.
3 | RESULTS
3.1 | Study search and study characteristics
The literature search resulted in 3664 articles, of which 65 articles
underwent full review and 29 were included in the final analysis
(Figure 1).3,7‐34 Among included studies, 19 were performed in China,
four in France, four in the United States, one in Brazil, and one in South
Korea. Eight studies were RCTs, four were prospective studies and the
remaining 17 were retrospective studies. Fifteen studies were published
and the remaining were prepublished. Seventeen studies had a drug or
intervention being tested with a control group for comparison. For
intervention, 12 studies used HCQ based treatment (two studies had
azithromycin along with HCQ in same arm, three had azithromycin in
separate arm, and one study was comparison of HCQ with Lopinavir/
Ritonavir), five studies used antiviral agents (two studies with Lopinavir/
Ritonavir, one with Baloxavir/Marboxil, and Favipravir and two with
Remdesivir), two were Tocilizumab based single‐arm studies, five used
corticosteroids (three with control arm) and five studies were single‐
arm plasma therapy based. There were 3624 patients in the interven-
tion arm (mean age: 55.9 ± 8.4 years, 62% males) and 1583 patients
(mean age: 52.5 ± 8.5 years, 60.7% males) in the control arm. The
median duration of follow‐up was 14 days (IQR: 9‐24.5) and the range
was 6 to 32 days across all studies. The demographics and study
characteristics have been provided in Table 1.
3.2 | Risk of bias assessment
Eight RCTs were part of this meta‐analysis. Of these three were at
low risk of bias and five were at high risk. Risk of bias summary has
been provided in Appendix 4.
3.3 | Primary outcome: all‐cause mortality
Twenty‐four studies provided data on mortality in the intervention arm
and the pooled all‐cause in‐hospital mortality rate was 12.8% (95% CI:
8.1%‐17.4%) for a median follow‐up duration of 14 (IQR: 10‐18.5) days
(Table 2). Comparing the mortality between the intervention arm and
F IGURE 1 PRISMA Flow diagram. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta‐Analyses
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control arms, 10 studies (n = 3894) provided the data, with a pooled
rate of 17.1% (95% CI: 9.1%‐27.4%) in the intervention arm and 14.8%
(95% CI: 9.4%‐20.1%) in the control arm, with no significant difference
between the two groups (OR: 1.36; 95% CI: 0.97‐1.89; I2 = 46%; P = .07)
(Figure 2A). The NNH was calculated to be 43. When analysis was
restricted to only four HCQ based studies (n = 3152), the mortality was
significantly higher in the HCQ group (OR: 1.86; 95% CI: 1.38‐2.50;
I2 = 29%; P < .001) (NNH—13). (Figure 2B) A further subgroup analysis
for only two studies (n = 212) which used only HCQ for treatment
without any other confounders like azithromycin and the mortality was
still significantly higher in the HCQ group (OR: 2.17; 95% CI: 1.26‐3.72;
I2 = 43%) (NNH—9). Comparing intervention and control arms, sub-
group analysis performed for antiviral studies only (n = 550) (OR: 0.83;
95% CI: 0.49‐1.38), steroid‐based studies (n = 192) (OR: 0.96; 95% CI:
0.40‐2.31), moderate to severe disease patients (n = 2184) (OR: 1.09;
95% CI: 0.56‐1.57), severe disease patients (n = 627) (OR: 0.87; 95% CI:
0.58‐1.31) (Appendix Figure 1) and RCTs only (n = 550) (OR: 0.83; 95%
CI: 0.49‐1.38) (Appendix Figure 2), did not show a statistically significant
difference between the two groups (Appendix Table 1).
3.4 | Secondary outcomes
3.4.1 | Rate of mechanical ventilation
Nine studies (n = 1456) reported need for mechanical ventilation in
patients in the intervention arm, with a pooled intubation rate of
18.6% (95% CI: 10.9%‐26.3%) (Table 2). Comparing the seven studies
(n = 2317) which also provided information on control population, the
pooled rates in the intervention and control arms were 13.5% vs
9.8%, respectively, with no significant difference between the
two groups (OR: 1.58; 95% CI: 0.60‐4.15; I2 = 85%) (NNT—27)
(Figure 3A). There was no significant difference in the outcome when
analysis was restricted to HCQ and antiviral based studies.
3.4.2 | Viral clearance
Fifteen studies reported data on either the proportion of patients
with antiviral clearance at the end of the study or the median
duration for antiviral clearance. The pooled proportion of patients
with antiviral clearance in the intervention arm (n = 393) was 80%
(95% CI: 70.7%‐89.4%). Comparing the six studies (n = 461) re-
porting data on antiviral clearance in intervention and control
groups, the pooled rates were 74.9% vs 66.8%, respectively, with no
significant difference between the two groups (OR: 1.86; 95% CI:
0.76‐4.54; I2 = 58%) (NNT—10) (Appendix Figure 3). When the
analysis was restricted to HCQ based and antiviral based studies,
there was still no significant difference between the two groups.
The median duration for antiviral clearance in the intervention arm
(n = 308) was 6.1 (IQR: 4.3‐8.8) days and in the control arm (n = 170)
was 9 (IQR: 4.5‐14) days, with no significant difference between the
two groups (P = .37).T
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F IGURE 2 A, Odds ratio comparing all‐cause in hospital mortality in intervention and control arms. B, Odds ratio comparing all‐cause in
hospital mortality in intervention and control arms in hydroxychloroquine based studies
F IGURE 3 A, Odds ratio comparing rates of mechanical ventilation in intervention and control arms. B, Odds ratio comparing clinical
recovery rates in intervention and control arms
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3.4.3 | Clinical recovery
Fourteen studies reported data on either the proportion of patients
who had clinical recovery or median time to clinical recovery. The
pooled rate of proportion of patients with clinical recovery in the
intervention arm (n = 558) was 79.7% (95% CI: 78.9%‐88.4%). Com-
paring the four studies reporting data in intervention and control arms,
the pooled rates were 64.1% and 52.8% (NNT—9), respectively with no
significant difference between the two groups (OR: 1.41; 95% CI: 0.99‐
2.02; I2 = 0%) (Figure 3B). Decrease in oxygen requirements in both
groups was reported in two studies (n = 375), with no significant dif-
ference between both the groups (OR: 1.05; 95% CI: 0.65‐1.71; I2 = 3%).
The median time to clinical recovery was 14 (IQR: 8.2‐19) days in
the intervention group (n = 451) and 16 (IQR: 14.3‐22) days in the
control group (n = 263), with no significant difference between the
two groups (P = .25).
3.4.4 | Progression to severe disease
Nine studies reported data on worsening of clinical status in the
hospital in mild‐moderate severity patients, with a pooled rate of
11.6% (95% CI: 5.4%‐17.8%) in the intervention arm (n = 387) over a
median duration of 13 (IQR: 9.5‐19.5) days. Comparing the pooled
rates in five studies reporting the outcome in both groups (n = 386),
the pooled rates were 13.4% and 12.8% in the intervention and
control groups, respectively, with no significant difference between
the two groups (OR: 1.19; 95% CI: 0.67‐2.13, I2 = 0%). Subgroup
analysis restricted to HCQ based and antiviral studies also did not
reveal any significant difference.
3.4.5 | Adverse events
Sixteen studies (n = 791) reported the rate of adverse events in the
intervention group with a pooled adverse event rate of 23.3% (95%
CI: 12.1%‐34.5%). Six studies (n = 754) compared intervention and
control groups with pooled adverse event rates of 34% and 29.5%,
respectively, with no significant difference between the two groups
(OR: 1.44; 95% CI: 0.70‐2.94) (NNT—22) (Figure 4A). On subgroup
analysis, the incidence of adverse events was significantly higher in
the HCQ group (OR: 3.88; 95% CI: 1.60‐9.45; I2 = 0%) (Figure 4B)
with an NNH of 7, but there was no significant difference for studies
with antiviral agents.
There was also no significant difference between both the groups
in radiological improvement and discharge rates. The individual pooled
rates and ORs are provided in Table 2. Subgroup analysis for only
RCTs for available outcomes is provided in Appendix Table 2.
4 | DISCUSSION
In this systematic review and meta‐analysis of 5207 patients from
29 studies, pooled outcome for any therapeutic intervention includ-
ing HCQ, Remdesivir, Lopinavir/Ritonavir, Steroids, Tocilizumab,
Convalescent plasma therapy did not show a survival benefit com-
pared to control arms. HCQ use was associated with significantly
increased all‐cause inpatient mortality and adverse event rates.
There were no significant benefits with any therapeutic intervention
in changing the natural history of SARS‐CoV‐2 infection assessed in
terms of rate of mechanical ventilation, viral clearance, time to
discharge, time to clinical recovery, and radiological improvement.
F IGURE 4 A, Odds ratio comparing adverse events rates in intervention and control arms. B, Odds ratio comparing adverse events in
intervention and control arms in HCQ based studies. HCQ, hydroxychloroquine
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HCQ increases the endosomal pH and prevents fusion of the host
membrane with SARS‐CoV‐2 thereby interfering with the viral
replication cycle. Several preclinical studies showed in vitro activity
against SARS‐CoV‐2 leading to clinical use of HCQ in COVID‐19
disease.35,36 An initial case series of 26 patients from France com-
paring HCQ and control groups suggested that HCQ leads to rapid
antiviral clearance in 70% of patients compared to 12.5% in controls.
This study was fraught with methodological inconsistencies like en-
rollment of asymptomatic individuals, omission of six patients from
analysis (HCQ patients of whom one died and three were transferred
to intensive care unit).9 In a randomized study of 62 patients from
China, patients treated with HCQ showed radiological improvement in
resolution of lung lesions as well as reduction in clinical progression of
disease. The commonality of the initial studies on HCQ was a relatively
small sample size, inappropriate control groups, lack of clarity in de-
fining the study outcomes.14 Two larger prospective RCTs from France
and Brazil show that HCQ/chloroquine use is associated with in-
creased incidence of cardiac events with no survival benefit.12,16 In
view of conflicting data outcomes, the National Institute of Health
(NIH), United States recommends that there is insufficient clinical data
to recommend either for or against using chloroquine or HCQ for the
treatment of COVID‐19.37 There have also been reports of severe
drug reaction with generalized exanthematous pustulosis reported
with HCQ use.38 Despite these issues, HCQ is currently one of the
most commonly used medications in various parts of the world. Our
analysis shows that HCQ based regimens had increased rate of mor-
tality (NNH—13) and adverse events (NNH—7) compared to control
patients. We hope our meta‐analysis adds more evidence to dampen
its use in view of lack of benefit and increased side effects.
Remdesivir was originally designed for use against Ebola. Remdesivir
was studied in severe COVID‐19 in China showed that the drug did not
show any benefit in terms of time to recovery as well as 28‐day mortality
outcome, though the study was terminated prematurely in view of dif-
ficulty in patient accrual.22 ACTT NIH study showed that Remdesivir
accelerated the time to recovery to 11 days compared to 15 days in the
placebo arm with no mortality benefit. This prompted an emergency
Food and Drug Administration authorization for use in COVID‐19
patients. There are calls for Remdesivir to be taken as the standard of
care control in future clinical studies. There have been questions raised
about the NIH study due to limitations such as change in the primary
endpoint of study after initiation of the trial, lack of mortality benefit;
study in moderate disease patients who tend to recover spontaneously
by the end of second week.39 There are ethical concerns among the
scientific community that drugs without proven mortality benefit or re-
duction in the need for ventilatory support may be promoted in view of
aggressive pharmaceutical lobbying. The current pandemic rings echo
bells of the 2009 H1N1 pandemic and the desperate stockpiling of
oseltamivir, whose proclaimed efficacy was claimed to be a byproduct
of concealed information and aggressive lobbying by pharmaceutical
companies.40 The published or preprint data for other drugs like Favi-
pravir, Baloxavir/Marboxil, corticosteroids, convalescent plasma are
currently insufficient to make any specific recommendation and our
meta‐analysis also suggests the same.
Our meta‐analysis shows that none of the so far studied inter-
ventions have a tangible benefit to change the course of disease
outcomes with the current published evidence. The clinical studies
that compare various interventions like the WHO sponsored soli-
darity trial that compares Remdesivir, chloroquine, or HCQ, lopinavir
plus ritonavir, and interferon‐beta with control arm and has all‐cause
mortality as the primary outcome is the need of the hour and the
results are eagerly awaited.41
The strengths of our study are as follows: we included 29 studies
with more than 5200 patients in our analysis with various inter-
ventions. Our review is extensive, by including the available inter-
ventions and providing clinically relevant outcomes in comparison
with controls. Several subgroup analyses were also performed based
on study interventions and design. Heterogeneity in most of our
outcomes was mild to moderate but we performed subgroup analysis
in RCTs to further reduce the heterogeneity.
4.1 | Limitations
Our study has several limitations. The study design, patient popula-
tion, and the outcomes assessed were variable in different studies.
Even though the intervention arms were clearly defined in most
studies, some of the patients in those arms also received other
medications and outcomes for such patients could not be excluded
separately, which could have confounded the results. Different levels
of disease severity of patients on study entry could lead to hetero-
geneity in outcomes but we tried to address it by performing sub-
group analyses based on disease severity for outcomes when
possible. Duration of follow‐up was variable across studies and entire
patient data at the end of study may not have been represented
which is a limitation of the published literature. Adverse events
reported include medication‐related adverse events and also symp-
toms in both groups, which could be related to SARS‐CoV‐2, but this
was unanimously reported across all studies. The dose of medica-
tions, especially HCQ, was variable in studies and dose based analysis
could not be performed. Data from prepublished studies were also
included in our analysis but we had included them to provide a more
comprehensive overview to prevent misinterpretation of results to
the best of our capabilities. The results of our study should hence be
interpreted with caution keeping these limitations in mind.
5 | CONCLUSIONS
In this meta‐analysis, there was no overall mortality or clinical benefit for
most therapeutic interventions but the use of HCQ was associated
with increased mortality rates and increased risk of adverse events in
SARS‐CoV‐2 patients. None of the other therapeutic interventions like
Lopinavir/Ritonavir, Remdesivir, Tocilizumab seemed to alter the natural
clinical course of the disease based on the available literature. There is a
need for well‐designed randomized clinical trials to further investigate the
efficacy and safety of various therapeutic interventions.
THOGULUVA CHANDRASEKAR ET AL. | 9
CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.
AUTHOR CONTRIBUTIONS
VTC: conceptualization of the study, data extraction, statistical
analysis, drafting of the manuscript, final approval of the manu-
script. BV: conceptualization of the study, data extraction, drafting
of the manuscript, final approval of the manuscript. HKP: data
extraction, critical revision of the manuscript, final approval of the
manuscript. MS: Data extraction, critical revision of the manu-
script, final approval of the manuscript. JM: critical revision of the
manuscript, final approval of the manuscript. MR: conceptualiza-
tion of the study, critical revision of the manuscript, final approval
of the manuscript.
ORCID
Viveksandeep Thoguluva Chandrasekar http://orcid.org/0000-0001-
5256-4113
Bhanuprasad Venkatesalu http://orcid.org/0000-0003-2541-2055
REFERENCES
1. The species Severe acute respiratory syndrome‐related coronavirus:
classifying. ‐nCoV and naming it SARS‐CoV‐2. Nature microbiology.
2020;5(4):536‐544.
2. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID‐19
[published online ahead of print April 24, 2020]. The N Engl J Med.
https://doi.org/10.1056/NEJMcp2009249
3. Guan W‐j, Ni Z‐Y, Hu Y, et al. Clinical characteristics of coronavirus
disease 2019 in China. The N Engl J Med. 2020;382(18):1708‐1720.
4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From
the Coronavirus Disease 2019 (COVID‐19) Outbreak in China:
Summary of a Report of 72314 Cases From the Chinese Center for
Disease Control and Prevention. JAMA. 2020;323(13):1239‐1242.
https://doi.org/10.1001/jama.2020.2648
5. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items
for systematic reviews and meta‐analyses: the PRISMA statement.
BMJ. 2009;339:b2535.
6. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration's
tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
7. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly
with mild to moderate COVID‐19: an open‐label, randomized, con-
trolled trial. BMJ. 2020;369. https://doi.org/10.1136/bmj.m1849
8. Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect
of a combination of hydroxychloroquine and azithromycin in
80 COVID‐19 patients with at least a six‐day follow up: a pilot
observational study [published online ahead of print April 11, 2020].
Travel Med Infect Dis. 34:101663. https://doi.org/10.1016/j.tmaid.
2020.101663
9. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azi-
thromycin as a treatment of COVID‐19: results of an open‐label non‐
randomized clinical trial [published online ahead of print March 20,
2020]. Int J Antimicro Ag. 105949. https://doi.org/10.1016/j.ijantimicag.
2020.105949
10. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxy-
chloroquine in hospitalized patients with covid‐19. The N Engl J Med.
2020;382:2411‐2418.
11. Mahevas M, Tran V‐T, Roumier M, et al. No evidence of clinical effi-
cacy of hydroxychloroquine in patients hospitalized for COVID‐19
infection with oxygen requirement: results of a study using routinely
collected data to emulate a target trial. medRxiv. 2020. https://doi.
org/10.1101/2020.04.10.20060699
12. Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid
antiviral clearance or clinical benefit with the combination of hydro-
xychloroquine and azithromycin in patients with severe COVID‐19
infection. Med Mal Infect. 2020;50:384.
13. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxy-
chloroquine usage in United States veterans hospitalized with Covid‐19.
2020. https://doi.org/10.1101/2020.04.16.20065920
14. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in pa-
tients with COVID‐19: results of a randomized clinical trial. 2020.
https://doi.org/10.1101/2020.03.22.20040758
15. Chen J, Li D, Ping L, et al. A pilot study of hydroxychloroquine in
treatment of patients with moderate COVID‐19. Zhejiang Da Xue Xue
Bao Yi Xue Ban. 2020;49(2):215‐219.
16. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses
of chloroquine diphosphate as adjunctive therapy for patients hos-
pitalized with severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) infection: a randomized clinical trial. JAMA Network
Open. 2020;3(4):e208857.
17. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for
critically Ill patients with SARS Q1‐CoV‐2 infection. Chest. 2020;158:
e9‐e13.
18. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute
Respiratory Distress Syndrome and Death in Patients With Coronavirus
Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;
180(7):934‐943. https://doi.org/10.1001/jamainternmed.2020.0994
19. Wang Y, Jiang W, He Q, et al. Early, low‐dose and short‐term appli-
cation of corticosteroid treatment in patients with severe COVID‐19
pneumonia: single‐center experience from Wuhan, China. medRxiv.
2020. https://doi.org/10.1101/2020.03.06.20032342
20. Xu X, Han M, Li T, et al. Effective treatment of severe COVID‐19 patients
with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970‐10975.
21. Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID‐19: A single
center experience. J Med Virol. 2020;92(7):814‐818. https://doi.org/
10.1056/NEJMcp2009249
22. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe
COVID‐19: a randomised, double‐blind, placebo‐controlled, multi-
centre trial. Lancet. 2020;395:1569‐1578.
23. Grein J, Ohmagari N, Shin D, et al. Compassionate use of
remdesivir for patients with severe covid‐19. The N Engl J Med.
2020;382:2327‐2336.
24. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for
COVID‐19 patients in Wuhan, China [published online ahead of print
April 15, 2020]. J Med Virol. https://doi.org/10.1002/jmv.25882
25. Lu X, Chen T, Wang Y, et al. Adjuvant corticosteroid therapy for
critically ill patients with COVID‐19. Crit Care. 2020. https://doi.org/
10.1101/2020.04.07.20056390
26. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults
hospitalized with severe covid‐19. N Engl J Med. 2020;382(19):1787‐1799.
27. Li Y, Xie Z, Lin W, et al. An exploratory randomized controlled study
on the efficacy and safety of lopinavir/ritonavir or arbidol treating
adult patients hospitalized with mild/moderate COVID‐19 (ELACOI).
medRxiv. 2020. https://doi.org/10.1101/2020.03.19.20038984
28. Lou Y, Liu L, Qiu Y. Clinical Outcomes and Plasma Concentrations
of Baloxavir Marboxil and Favipiravir in COVID‐19 Patients: an
Exploratory Randomized, Controlled Trial. medRxiv. 2020. https://
doi.org/10.1101/2020.04.29.20085761
29. Fang X, Mei Q, Yang T, et al. Low‐dose corticosteroid therapy does
not delay viral clearance in patients with COVID‐19. J Infect. 2020;81:
147‐178.
30. Duan K, Liu B, Li C, et al. The feasibility of convalescent plasma
therapy in severe COVID‐19 patients: a pilot study. medRxiv. 2020.
https://doi.org/10.1101/2020.03.16.20036145
10 | THOGULUVA CHANDRASEKAR ET AL.
31. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with
COVID‐19 with convalescent plasma. JAMA. 2020;323(16):1582‐1589.
32. Huang M, Tang T, Pang P, et al. Treating COVID‐19 with chloroquine.
J Mol Cell Biol. 2020;12:322‐325.
33. Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in
two COVID‐19 patients with acute respiratory distress syndrome in
Korea. J Korean Med Sci. 2020;35(14):e149.
34. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment
with hydroxychloroquine or azithromycin with in‐hospital mor-
tality in patients with COVID‐19 in New York State. JAMA. 2020;
323(24):2493‐2502.
35. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent
inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
36. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of
chloroquine, is effective in inhibiting SARS‐CoV‐2 infection in vitro.
Cell Discov. 2020;6:16.
37. COVID‐19 Treatment Guidelines Panel Coronavirus Disease 2019
(COVID‐19) Treatment Guidelines National Institutes of Health Avail-
able at https://wwwcovid19treatmentguidelinesnihgov/. Accessed May
14, 2020.
38. Schwartz R, Janniger C. Generalized pustular figurate erythema: a
newly delineated severe cutaneous drug reaction linked with hydro-
xychloroquine. Dermatol Ther. 2020;33(3):e13380.
39. NIH clinical trial shows Remdesivir accelerates recovery from advanced
COVID‐19. 2020. https://wwwnihgov/news-events/news-releases/nih-
clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19
40. Belluz J. Tug of war for antiviral drugs data. BMJ. 2014;348:
g2227.
41. I. Public health emergency SOLIDARITY trial of treatments for
COVID‐19 infection in hospitalized patients. BMC. 2020. https://doi.
org/10.1186/ISRCTN83971151
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section.
How to cite this article: Thoguluva Chandrasekar V,
Venkatesalu B, Patel HK, Spadaccini M, Manteuffel J, Ramesh
M. Systematic review and meta‐analysis of effectiveness of
treatment options against SARS‐CoV‐2 infection. J Med Virol.
2020;1–11. https://doi.org/10.1002/jmv.26302
THOGULUVA CHANDRASEKAR ET AL. | 11
